Combined Screening with PLGF (Delfia)

Combined Screening with PLGF (Delfia) is an advanced first-trimester prenatal screening test used to assess the risk of chromosomal abnormalities and pregnancy-related complications in the developing fetus. This screening combines maternal blood biomarkers, ultrasound findings, and maternal age to provide a more accurate risk assessment during early pregnancy.

The inclusion of PLGF (Placental Growth Factor) improves the prediction of placental disorders such as Preeclampsia and supports enhanced fetal risk evaluation.

Test Purpose

This screening helps evaluate the risk of:

• Down Syndrome (Trisomy 21)
• Edwards Syndrome (Trisomy 18)
• Patau Syndrome (Trisomy 13)
• Early-onset Preeclampsia
• Placental insufficiency-related complications
• Fetal growth restriction risk assessment

What is Measured?

The test typically combines:

• PLGF (Placental Growth Factor)
• Free Beta hCG
• PAPP-A (Pregnancy Associated Plasma Protein-A)
• Nuchal Translucency (NT Scan)
• Maternal age and clinical history

The Delfia technology platform offers highly sensitive and reliable biomarker analysis for prenatal screening.

Recommended Timing

• Usually performed between 11 weeks and 13 weeks + 6 days of pregnancy.

Symptoms / Conditions Where Recommended

Doctors may advise this screening if:

• Maternal age is above 30–35 years
• Previous pregnancy with chromosomal abnormalities
• Family history of genetic disorders
• High-risk pregnancy
• Hypertension or risk of preeclampsia
• IVF or assisted pregnancies

Sample Required

• Maternal Blood Sample
• Combined with NT Ultrasound findings

Preparation

• No fasting is generally required.
• Carry previous pregnancy scans/reports if available.
• NT scan details should be available during interpretation.

Benefits of the Test

• Early fetal risk assessment
• Non-invasive prenatal screening
• Improved preeclampsia prediction with PLGF
• Helps guide further diagnostic testing if needed
• Supports better pregnancy monitoring and management

Interpretation

• Low Risk: Reduced probability of chromosomal abnormalities.
• High Risk: Additional diagnostic tests such as NIPT, CVS, or amniocentesis may be recommended by the doctor.

Important Note

This is a screening test, not a confirmatory diagnostic test. Abnormal results should always be interpreted by a qualified obstetrician or fetal medicine specialist.